Identification of a predictive factor of metastatic castration-resistant prostate cancer patients’ response to alternative antiandrogen therapy with flutamide. This is an ASCO Meeting Abstract from ...
A new mathematical model which aims to optimise treatment for prostate cancer has been developed by experts at the University of Portsmouth. Prostate cancer is the second most common cancer among men ...
ASPIRE trial explores survival benefits of adding chemotherapy to standard prostate cancer treatment
The Alliance for Clinical Trials in Oncology is now enrolling patients in the ASPIRE trial (A032302)-a large-scale, phase III ...
It remains unknown whether or not short-term androgen deprivation (STAD) improves survival among men with intermediate-risk prostate cancer (IRPC) treated with dose-escalated radiotherapy (RT).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results